The position statement from cancer and bone societies updates recommendations from 2017 for managing bone loss and fracture ...

BERLIN -- For the first time in a phase III trial, adjuvant treatment with a CDK4/6 inhibitor significantly improved overall ...

These Phase III results could enhance Verzenio’s uptake alongside ET in the adjuvant breast cancer setting, if approved.

Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with gedatolisib + palbociclib + fulvestrant ...

Gedatolisib combined with fulvestrant, with or without palbociclib, significantly improved PFS in HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. The triplet regimen reduced ...

Now four years into a first-in-class FDA approval for certain HR-positive, HER2-negative early breast cancers, Eli Lilly’s ...

At ESMO 2025, Eli Lilly’s Verzenio and Novartis’ Kisqali both demonstrated durable efficacy in hormone receptor-positive, ...

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk ...

Abemaciclib plus endocrine therapy significantly improves overall survival in high-risk early breast cancer, reducing death risk by 15.8% compared to endocrine therapy alone.

The approval was based on a comprehensive clinical data package that included a phase 3 trial comparing denosumab-qbde with Prolia in 473 women with postmenopausal osteoporosis.

Researchers appear to have found a solution for breast cancer patients who do not respond well enough to a common treatment.